Abstract:AIMS:We conducted a presentation on an 84-year-old male patient who has been diagnosed with TTRA81V (p. TTRA101V) hereditary transthyretin cardiac amyloidosis (hATTR-CM). In order to establish its pathogenicity, we extensively investigated the biochemical and biophysical properties of the condition. METHODS AND RESULTS:Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly acknowledged progressive infiltrative cardiomyopathy that leads to heart failure and potentially fatal arrhythmias. Gaining a comprehensive understanding of the biochemical and biophysical characteristics of genetically mutated TTR proteins serves as the fundamental cornerstone for delivering precise medical care to individuals affected by ATTR. Laboratory assessments indicated a brain natriuretic peptide of 200.12 ng/L (normal range: 0-100 ng/L) and high-sensitivity cardiac troponin I of 0.189 μg/L (normal range: 0-0.1 μg/L). Echocardiography identified left atrial enlargement, symmetrical left ventricular hypertrophy (16 mm septal and 16 mm posterior wall), and a left ventricular ejection fraction of 56%. Cardiac-enhanced magnetic resonance imaging revealed subendocardial late gadolinium enhancement. Tc-99m-PYP nuclear scintigraphy confirmed grade 3 myocardial uptake, showing an increased heart-to-contralateral ratio (H/CL = 2.33). Genetic testing revealed a heterozygous missense mutation in the TTR gene (c.302C>T), resulting in an alanine-to-valine residue change (p. Ala81Val, following the first 20 residues of signal sequence nomenclature). Biochemical analysis of this variant displayed compromised kinetic stability in both the TTRA81V:WT (wild-type) heterozygote protein (half-life, t1/2 = 21 h) and the TTRA81V homozygote protein (t1/2 = 17.5 h). The kinetic stability fell between that of the TTRWT (t1/2 = 42 h) and the early-onset TTRL55P mutation (t1/2 = 4.4 h), indicating the patient's late-onset condition. Kinetic stabilizers (Tafamidis, Diflunisal, and AG10) all exhibited the capacity to inhibit TTRA81V acid- and mechanical force-induced fibril formation, albeit less effectively than with TTRWT. Chromatographic assessment of the patient's serum TTR tetramers indicated a slightly lower concentration (3.0 μM) before oral administration of Tafamidis compared with the normal range (3.6-7.2 μM). CONCLUSIONS:We identified a patient with hATTR-CM who possesses a rare TTRA81V mutation solely associated with cardiac complications. The slightly reduced kinetic stability of this mutation indicates its late-onset nature and contributes to the gradual progression of the disease.

Chemical modification of transthyretin in familial amyloidotic polyneuropathy

An ultra performance liquid chromatography method for transthyretin variants screening and heart failure assisting diagnosis

Clinical and Histopathological Features of Familial Amyloidotic Polyneuropathy with Transthyretin Val30Ala in a Chinese Family

A Study of Familial Amyloid Polyneuropathy Induced by the TTR Val30Leu Mutation in China

The Impact of V30A Mutation on Transthyretin Protein Structural Stability and Cytotoxicity Against Neuroblastoma Cells.

Proteomics-based Analysis on the Detection of Serum Transthyretin Modification in Patients with Rheumatoid Arthritis

Analysis of Mitochondrial Haplogroups Associated with TTR Val30Ala Familial Amyloidotic Polyneuropathy in Chinese Patients

Clinical Features of Familial Amyloid Polyneuropathy Carrying Transthyretin Mutations in Four Chinese Kindreds

Clinical and biochemical characterization of asymptomatic carriers and symptomatic patients with hereditary transthyretin amyloidosis caused by TTR V30L mutation

Family Studies of Transthyretin (Prealbumin) and its Methionine 30 Variant in Portuguese Patients with Familial Amyloidotic Polyneuropathy

Effect of MPO/H2O2/NO(-) system on nitric oxide-mediated modification of TTR amyloid and serum TTR in FAP ATTR Val30Met patients.

Identification of a novel transthyretin mutation D39Y in a cardiac amyloidosis patient and its biochemical characterizations

REPORT OF CORPORA AMYLACEA IN GLANDULAR TISSUES IN PATIENTS WITH FAP

Histopathological features of familial amyloidotic polyneuropathy: a report of a case with postmortem examination

Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis

Clinical and Biochemical Characterization of Hereditary Transthyretin Amyloidosis Caused by E61K Mutation

Biochemical and Biophysical Properties of a Rare TTRA81V Mutation Causing Mild Transthyretin Amyloid Cardiomyopathy

Detection of ATTR aggregates in plasma of polyneuropathic ATTR-V30M amyloidosis patients

Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy

Structure-based probe reveals the presence of large transthyretin aggregates in plasma of ATTR amyloidosis patients

Characterization of Transthyretin Mutation G47V Associated with Hereditary Cardiac Amyloidosis